REFERENCES
1
1. Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers. Mar 18 2021;7(1):22.
2. Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Surg. Oncol. 2018;29(Suppl 4):iv267.
3. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.Ann. Surg. Oncol. 2004;11(5):465-475.
4. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.Lancet. 2009;373(9669):1097-1104.
5. Corless CL, Ballman KV, Antonescu CR, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014;32(15):1563-1570.
6. Guérin A, Sasane M, Keir CH, et al. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.JAMA oncol. 2015;1(6):797-805.
7. Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol. 2016;34(3):244-250.
8. Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. JAMA oncol. 2017;3(5):602-609.
9. Raut CP, Espat NJ, Maki RG, et al. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA oncol. 2018;4(12):e184060.
10. Joensuu H, Eriksson M, Sundby Hall K, et al. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA oncol.2020;6(8):1241-1246.
11. Cavnar MJ, Seier K, Curtin C, et al. Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras. Ann Surg. 2021;273(1):128-138.
12. Vincenzi B, Napolitano A, Fiocco M, et al. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2021.
13. Xu S-J, Zhang S-Y, Dong L-Y, Lin G-S, Zhou Y-J. Dynamic survival analysis of gastrointestinal stromal tumors (GISTs): a 10-year follow-up based on conditional survival. BMC cancer. 2021;21(1):1170.
14. Zhang Q, Xu J, Qian Y, et al. Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors. Mol Cancer Ther. 2018;17(12):2780-2787.
15. Wu X, Li J, Zhou Y, et al. Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor. Chemotherapy. 2018;63(6):301-307.
16. Xia Y, Chen S, Luo M, et al. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. Cancer. 2020;126 Suppl 9:2054-2061.
17. Ishikawa Y, Kiyoi H, Watanabe K, et al. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci. 2010;101(10):2186-2192.
18. Yin Y, Xiang J, Tang S, Chen J, Yu Q, Zhang B. A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment. Medicine (Baltimore). Dec 2016;95(49):e5488.
19. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. Jul 1 2009;27(19):3141-3147.
20. Bouchet S, Poulette S, Titier K, et al. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. Eur J Cancer. Apr 2016;57:31-38.
21. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia.2009;23(9):1537-1544.
22. National Comprehensive Cancer Network. Management of immunotherapy-related toxicities (Version 1.2020).https://www. nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed October 5, 2020.
23. Fornasaro S, Bonifacio A, Marangon E, et al. Label-Free Quantification of Anticancer Drug Imatinib in Human Plasma with Surface Enhanced Raman Spectroscopy. Anal Chem. 2018;90(21):12670-12677.
24. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. Sep 2008;168(6):656-664.
25. Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. J Clin Oncol. 2018;36(6):600-608.
26. Farag S, Verheijen RB, Martijn Kerst J, Cats A, Huitema ADR, Steeghs N. Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. Clin Pharmacokinet.2017;56(3):287-292.
27. Adiwidjaja J, Gross AS, Boddy AV, McLachlan AJ. Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens. Br J Clin Pharmacol. 2021:16.
2-27